Table 2 Clinical trial of the nano vaccine
Catalog | Name | Status | Identifier | Phase | Sponsor | Disease | Cancer type |
|---|---|---|---|---|---|---|---|
Liposome vaccine | Tecemotide (L-BLP25) | Completed | NCT00828009 | Phase 2 | ECOG-ACRIN Cancer Research Group | Non-Small Cell Lung Cancer | Stage IIIA Stage IIIB |
Completed | NCT00960115 | Phase 1/ Phase 2 | Merck KGaA, Darmstadt, Germany | Non-small Cell Lung Cancer | Stage III | ||
Completed | NCT00409188 | Phase 3 | EMD Serono | Non-small Cell Lung Cancer | Stage III | ||
Terminated | NCT01015443 | Phase 3 | Merck KGaA, Darmstadt, Germany | Non-small Cell Lung Cancer | Stage III | ||
Terminated | NCT00925548 | Phase 3 | EMD Serono | Breast Cancer | - | ||
Completed | NCT00157209 | Phase 2b | Merck KGaA, Darmstadt, Germany | Non-Small-Cell Lung | - | ||
Completed | NCT00157196 | Phase 2 | Merck KGaA, Darmstadt, Germany | Non-Small Cell Lung Cancer | Stage III | ||
Completed | NCT01496131 | Phase 2 | EMD Serono | Prostate Cancer | Untreated, Intermediate and High Risk | ||
Completed | NCT01094548 | Phase 2 | Merck KGaA, Darmstadt, Germany | Multiple Myeloma | no Symptoms /No Chemotherapy | ||
Terminated | NCT01423760 | Not Applicable | Merck KGaA, Darmstadt, Germany | Non-Small Cell Lung Cancer / Multiple Myeloma | - | ||
RNA-lipid Particle (RNA-LP) Vaccines | Recruiting | NCT04573140 | Phase 1 | University of Florida | Glioblastoma | - | |
W_ova1 Vaccine | Active, not recruiting | NCT04163094 | Phase 1 | University Medical Center Groningen | Ovarian Cancer | - | |
NY-ESO-1 peptide vaccine | Completed | NCT01673217 | Phase 1 | Roswell Park Cancer Institute | Recurrent Fallopian Tube Cancer/ Recurrent Ovarian /Epithelial Cancer Recurrent Primary Peritoneal Cavity Cancer | - | |
DPX-0907 | Completed | NCT01095848 | Phase 1 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Ovarian Neoplasms /Breast Neoplasms/ Prostatic Neoplasms | HLA-A2 Positive Advanced Stage | |
DOTAP liposome vaccine | Not yet recruiting | NCT05264974 | Phase 1 | University of Florida | Melanoma | - | |
ONT-10 | Completed | NCT01556789 | Phase 1 | Cascadian Therapeutics Inc. | Solid Tumors | Stage III or IV | |
Completed | NCT01978964 | Phase 1b | Cascadian Therapeutics Inc. | Solid Tumors | Stage III or IV | ||
PDS0101 | Recruiting | NCT04580771 | Phase 2 | M.D. Anderson Cancer Center | Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IB3-IVA | |
Recruiting | NCT05232851 | Phase 1 /Phase 2 | Mayo Clinic | Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer | - | ||
autologous tumor cell vaccine | Completed | NCT00020462 | Phase 1 | National Cancer Institute (NCI) | Lymphoma | - | |
Lipovaxin-MM | Completed | NCT01052142 | Phase 1 | Lipotek Pty Ltd | Melanoma | - | |
Oncoquest-CLL vaccine | Active, not recruiting | NCT01976520 | Phase 1 | XEME Biopharma Inc. | Chronic Lymphocytic Leukemia (CLL) | - | |
polyvalent melanoma vaccine | Completed | NCT00004104 | Phase 2 | NYU Langone Health | Melanoma (Skin) | Stage III | |
Liposomal Doxorubicin | Completed | NCT00923936 | Phase 2 | National Cancer Institute (NCI) | Sarcoma, Kaposi | - | |
Polymeric nanoparticles | Cetuximab nanoparticles | Unknown | NCT03774680 | Phase 1 | Ahmed A. H. Abdellatif | Colon Cancer/ Colo-rectal Cancer | - |
Docetaxel-PNP | Completed | NCT01103791 | Phase 1 | Samyang Biopharmaceuticals Corporation | Advanced Solid Malignancies | - | |
Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT) | Not yet recruiting | NCT05456022 | Phase 2 | Cairo University | Oral Cancer | - | |
Docetaxel-PNP | Completed | NCT02274610 | Phase 1 | Samyang Biopharmaceuticals Corporation | Solid Tumor | - | |
CRLX101 | Terminated | NCT03531827 | Phase 2 | National Cancer Institute (NCI) | Metastatic Castration Resistant Prostate Cancer Prostate Neoplasms | - | |
Virus-like particles | HPV-16/18 L1 virus-like particle/AS04 vaccine | Completed | NCT00128661 | Phase 3 | GlaxoSmithKline | Prevent Cervical Cancer/ Precancerous Condition | - |
| Â | HPV-16/18 vaccine | Completed | NCT02740777 | Phase 2 | Shanghai Zerun Biotechnology Co.,Ltd | Human Papillomavirus Cervical Intraepithelial Neoplasia Persistent Infection | - |
| Â | Â | Completed | NCT02733068 | Phase 3 | Shanghai Zerun Biotechnology Co.,Ltd | Cervical Intraepithelial Neoplasia | - |
| Â | 9vHPV Vaccine | Completed | NCT01651949 | Phase 3 | Merck Sharp & Dohme LLC | Genital Warts /Anal Cancer/ Anal Intraepithelial Neoplasia | - |
| Â | Â | Active, not recruiting | NCT04199689 | Phase 3 | Merck Sharp & Dohme LLC | Papillomavirus Infections | - |
| Â | Â | Completed | NCT03546842 | Phase 3 | Merck Sharp & Dohme LLC | Papillomavirus Infections Uterine Cervical Neoplasms Vulvar Neoplasms Vaginal Neoplasms | - |
| Â | Â | Active, not recruiting | NCT05285826 | Phase 3 | Merck Sharp & Dohme LLC | Papillomavirus Infections | - |
| Â | Quadrivalent HPV for types 6, 11, 16 and 18 | Completed | NCT01101750 | Phase 4 | Medstar Health Research Institute | Cervical Cancer/ Hpv /Warts | - |
| Â | Â | Completed | NCT00635830 | Phase 1 | Merck Sharp & Dohme LLC | HPV Infections | - |
| Â | Â | Completed | NCT00337428 | Phase 3 | Merck Sharp & Dohme LLC | Neoplasms, Glandular and Epithelial Diphtheria Tetanus Whooping Cough Poliomyelitis | - |
| Â | Â | Completed | NCT00834106 | Phase 3 | Merck Sharp & Dohme LLC | HPV Infections | - |
| Â | Â | Active, not recruiting | NCT03728881 | Phase 3 | National Cancer Institute (NCI) | Human Papillomavirus-Related Cervical Carcinoma | - |
| Â | Â | Completed | NCT00380367 | Phase 3 | Merck Sharp & Dohme LLC | Papillomavirus Infections | - |
| Â | Â | Completed | NCT04711265 | - | Kenya Medical Research Institute | HPV Infection HIV-1-infection | - |
| Â | Â | Completed | NCT00496626 | Phase 3 | Merck Sharp & Dohme LLC | Papillomavirus Infections | - |
| Â | Gardasil | Active, not recruiting | NCT00092534 | Phase 3 | Merck Sharp & Dohme LLC | Cervical Cancer Genital Warts | - |
| Â | Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949 | Terminated | NCT04387071 | Phase 1/ Phase 2 | University of Southern California | Pancreatic Cancer and Other Cancers Except Melanoma | Stage IV |
| Â | V501 | Completed | NCT01544478 | Phase 4 | Merck Sharp & Dohme LLC | Cervical Cancer Cervical Intraepithelial Neoplasia Adenocarcinoma in Situ | - |
| Â | Â | Completed | NCT00092495 | Phase 3 | Merck Sharp & Dohme LLC | Cervical Cancer Genital Warts | - |
| Â | Â | Completed | NCT00092495 | Phase 3 | Merck Sharp & Dohme LLC | Cervical Cancer Genital Warts | - |
| Â | Â | Completed | NCT00517309 | Phase 3 | Merck Sharp & Dohme LLC | Cervical Cancer Genital Warts | - |
| Â | Â | Completed | NCT00092482 | Phase 3 | Merck Sharp & Dohme LLC | Cervical Cancer Genital Warts | - |
| Â | Â | Completed | NCT00092547 | Phase 3 | Merck Sharp & Dohme LLC | Papillomavirus Infections | - |
| Â | Â | Completed | NCT01862874 | Phase 3 | Merck Sharp & Dohme LLC | Anogenital Human Papilloma Virus Infection /Condyloma Acuminata | - |
| Â | Â | Completed | NCT02576054 | Phase 3 | Merck Sharp & Dohme LLC | Anogenital Human Papilloma Virus Infection Condyloma Acuminata | - |
| Â | Â | Completed | NCT00411749 | Phase 2 | Merck Sharp & Dohme LLC | HPV Infections | - |
| Â | V503 | Completed | NCT00543543 | Phase 3 | Merck Sharp & Dohme LLC | Cervical Cancer Vulvar Cancer Vaginal Cancer Genital Warts Human Papillomavirus Infection | - |
| Â | Â | Completed | NCT03158220 | Phase 3 | Merck Sharp & Dohme LLC | Cervical Cancer Vulvar Cancer Vaginal Cancer Genital Warts Human Papillomavirus Infection | - |
| Â | Â | Active, not recruiting | NCT04635423 | Phase 3 | Merck Sharp & Dohme LLC | Neoplasms | - |
| Â | Â | Completed | NCT01254643 | Phase 3 | Merck Sharp & Dohme LLC | Papillomavirus Infections | - |
| Â | Â | Completed | NCT01984697 | Phase 3 | Merck Sharp & Dohme LLC | Human Papillomavirus Infection | - |
| Â | Â | Active, not recruiting | NCT03903562 | Phase 3 | Merck Sharp & Dohme LLC | Papillomavirus Infections | - |
| Â | Â | Completed | NCT02114385 | Phase 3 | Merck Sharp & Dohme LLC | Papilloma Viral Infection | - |
| Â | Â | Completed | NCT01073293 | Phase 3 | Merck Sharp & Dohme LLC | Papillomavirus Infections | - |
| Â | Â | Completed | NCT00988884 | Phase 3 | Merck Sharp & Dohme LLC | Human Papillomavirus Infection | - |
| Â | Â | Completed | NCT00943722 | Phase 3 | Merck Sharp & Dohme LLC | Cervical Cancers/ Vulvar Cancer/ Vaginal Cancer/ Genital Lesions/ PAP Test Abnormalities/ HPV Infections | - |
| Â | Â | Completed | NCT01047345 | Phase 3 | Merck Sharp & Dohme LLC | Cervical Cancers/ Vulvar Cancers/ Vaginal Cancers/ Genital Warts | - |
| Â | Â | Active, not recruiting | NCT02653118 | - | Merck Sharp & Dohme LLC | Cervical Cancer/ Vulvar Cancer/ Vaginal Cancer/ Genital Warts/ Human Papillomavirus Infection | - |
| Â | Â | Active, not recruiting | NCT03998254 | Phase 3 | Merck Sharp & Dohme LLC | Papillomavirus Infections | - |
| Â | V504 | Completed | NCT00551187 | Phase 2 | Merck Sharp & Dohme LLC | Cervical Cancer Vulvar Cancer Vaginal Cancer Genital Warts Human Papillomavirus Infection | - |
| Â | V505 | Completed | NCT00520598 | Phase 2 | Merck Sharp & Dohme LLC | Cervical Cancer Vulvar Cancer Vaginal Cancer Genital Warts Human Papillomavirus Infection | - |
| Â | Recombinant Human Papillomavirus Bivalent | Recruiting | NCT05045755 | - | Jun Zhang | Cervical Intraepithelial Neoplasia Cervical Cancer Vaginal Intraepithelial Neoplasia Vulvar Intraepithelial Neoplasia | - |
| Â | AAVLP-HPV | Completed | NCT03929172 | Phase 1 | 2Â A Pharma AB | Papillomavirus Infections | - |
|  | Gardasil® HPV vaccine | Active, not recruiting | NCT04953130 | Phase 4 | London School of Hygiene and Tropical Medicine | HPV Infection Vaccine Preventable Disease | - |
| Â | Â | Active, not recruiting | NCT00092534 | Phase 3 | Merck Sharp & Dohme LLC | Cervical Cancer Genital Warts | - |
| Â | Cervarix | Completed | NCT00586339 | Phase 2 | GlaxoSmithKline | Infections, Papillomavirus | - |